Optimer Pharmaceuticals (Nasdaq: OPTR) is expected to report Q2 earnings on Aug. 1. Here's what Wall Street wants to see:

The 10-second takeaway
 Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Optimer Pharmaceuticals's revenues will decrease -57.2% and EPS will remain in the red.

The average estimate for revenue is $21.3 million. On the bottom line, the average EPS estimate is -$0.62.

Revenue details
 Last quarter, Optimer Pharmaceuticals reported revenue of $19.4 million. GAAP reported sales were 35% higher than the prior-year quarter's $14.4 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 Last quarter, EPS came in at -$0.65. GAAP EPS were -$0.65 for Q1 compared to -$0.23 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
 For the preceding quarter, gross margin was 83.1%, 100 basis points worse than the prior-year quarter. Operating margin was -162.0%, much better than the prior-year quarter. Net margin was -161.2%, much worse than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $89.2 million. The average EPS estimate is -$2.28.

Investor sentiment
 The stock has a one-star rating (out of five) at Motley Fool CAPS, with 103 members out of 143 rating the stock outperform, and 40 members rating it underperform. Among 46 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 33 give Optimer Pharmaceuticals a green thumbs-up, and 13 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Optimer Pharmaceuticals is hold, with an average price target of $17.50.